Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pimecrolimus
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2024
Lead Product(s) : Pimecrolimus
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Viatris
Deal Size : $280.0 million
Deal Type : Acquisition
Details : With the combination of Viatris' global commercial footprint, R&D and regulatory capabilities, along with Famy Life Sciences' Phase III-ready pipeline, the Company believes it has the foundation to create a leading global ophthalmology franchise.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Viatris
Deal Size : $280.0 million
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Viatris
Deal Size : Undisclosed
Deal Type : Acquisition
Details : With the combination of Viatris' global commercial footprint, R&D and regulatory capabilities, along with Famy Life Sciences' Phase III-ready pipeline, the Company believes it has the foundation to create a leading global ophthalmology franchise.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 11, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Viatris
Deal Size : Undisclosed
Deal Type : Acquisition